Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -18.85 is 94% above its 5-year average of -316.96, near the high end of its 5-year range (-1415.25–-18.85).
60.42% above its 12-month average of -47.63.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -3.40.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 22 comparable quarters.
EARNINGS PER SHARE (EPS)
-18.85
EARNINGS PER SHARE (EPS) AVG TTM
-47.63
EARNINGS PER SHARE (EPS) AVG 3Y
-99.69
EARNINGS PER SHARE (EPS) AVG 5Y
-316.96
EARNINGS PER SHARE (EPS) AVG 10Y
-783.50
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+60.42%
CURRENT VS 3Y AVG
+81.09%
CURRENT VS 5Y AVG
+94.05%
CURRENT VS 10Y AVG
+97.59%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ernexa Therapeutics Inc.
Market Cap
$4.04M
Earnings Per Share (EPS)
-18.85
TTM Avg
-47.63
3Y Avg
-99.69
5Y Avg
-316.96
Market Cap
$4.00M
Earnings Per Share (EPS)
-211.18
TTM Avg
-432751.00
3Y Avg
-875189.50
5Y Avg
-22462429.83
Market Cap
$4.10M
Earnings Per Share (EPS)
-5.60
TTM Avg
-53.55
3Y Avg
-292.57
5Y Avg
-468.76
Market Cap
$3.57M
Earnings Per Share (EPS)
-14.40
TTM Avg
-19.95
3Y Avg
-16.43
5Y Avg
-17.45
Market Cap
$4.15M
Earnings Per Share (EPS)
N/A
TTM Avg
-60.73
3Y Avg
-46926.80
5Y Avg
-32538.00
Market Cap
$4.21M
Earnings Per Share (EPS)
-0.76
TTM Avg
-0.88
3Y Avg
-0.66
5Y Avg
-0.44
Market Cap
$3.55M
Earnings Per Share (EPS)
-0.91
TTM Avg
-1.99
3Y Avg
-3.92
5Y Avg
-2.83
Market Cap
$3.49M
Earnings Per Share (EPS)
-0.45
TTM Avg
-1.48
3Y Avg
-5.05
5Y Avg
-8.12
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | $4.04M | -18.85 | -47.63 | -99.69 | -316.96 |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.00M | -211.18 | -432751.00 | -875189.50 | -22462429.83 |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.10M | -5.60 | -53.55 | -292.57 | -468.76 |
| Nexalin Technology, Inc. (NXL)vs › | $3.57M | -14.40 | -19.95 | -16.43 | -17.45 |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A | -60.73 | -46926.80 | -32538.00 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.21M | -0.76 | -0.88 | -0.66 | -0.44 |
| Evogene Ltd. (EVGN)vs › | $3.55M | -0.91 | -1.99 | -3.92 | -2.83 |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | -0.45 | -1.48 | -5.05 | -8.12 |
| Eocene Ltd. (EOCN)vs › | $3.46M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.40M | N/A | -130.80 | -71.47 | -57.18 |
Trailing EPS (TTM)
$-18.85
Forward EPS (Est.)
$-18.02
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -56.00 |
| 2024-12-31 | -39.25 |
| 2023-12-31 | -102.00 |
| 2022-12-31 | -201.50 |
| 2021-12-31 | -1415.25 |
| 2020-12-31 | -87.75 |
| 2019-12-31 | -712.00 |
| 2018-12-31 | -96.25 |
| 2017-12-31 | -441.00 |
| 2016-12-31 | -1536.00 |
| 2015-12-31 | -3931.50 |
